2309 Stock Overview
CMIC HOLDINGS Co., Ltd. provides pharmaceutical development services in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
CMIC HOLDINGS Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,644.00 |
| 52 Week High | JP¥2,657.00 |
| 52 Week Low | JP¥1,616.00 |
| Beta | 0.56 |
| 1 Month Change | 0.11% |
| 3 Month Change | 0.076% |
| 1 Year Change | 26.57% |
| 3 Year Change | 69.81% |
| 5 Year Change | 70.69% |
| Change since IPO | 76.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2309 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 0.2% | -4.4% | -0.7% |
| 1Y | 26.6% | -34.5% | 27.0% |
Return vs Industry: 2309 exceeded the JP Life Sciences industry which returned -28.6% over the past year.
Return vs Market: 2309 underperformed the JP Market which returned 35.7% over the past year.
Price Volatility
| 2309 volatility | |
|---|---|
| 2309 Average Weekly Movement | 0.3% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 2309 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2309's weekly volatility has decreased from 6% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 4,684 | Kazuo Nakamura | www.cmicgroup.com |
CMIC HOLDINGS Co., Ltd. provides pharmaceutical development services in Japan. The company offers clinical trial services, including audit and quality assurance, clinical operations and trials, data management, clinical caretaker, patient recruitment, pharmacovigilance, project management, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance/drug pricing, and product life cycle management consulting services. It also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, and technology transfer, as well as formulation development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as efficacy and safety pharmacology, in vitro and in vivo, and non-clinical studies.
CMIC HOLDINGS Co., Ltd. Fundamentals Summary
| 2309 fundamental statistics | |
|---|---|
| Market cap | JP¥44.69b |
| Earnings (TTM) | JP¥5.33b |
| Revenue (TTM) | JP¥93.11b |
8.4x
P/E Ratio0.5x
P/S RatioIs 2309 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2309 income statement (TTM) | |
|---|---|
| Revenue | JP¥93.11b |
| Cost of Revenue | JP¥72.30b |
| Gross Profit | JP¥20.81b |
| Other Expenses | JP¥15.48b |
| Earnings | JP¥5.33b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 315.19 |
| Gross Margin | 22.35% |
| Net Profit Margin | 5.72% |
| Debt/Equity Ratio | 7.1% |
How did 2309 perform over the long term?
See historical performance and comparison